M. Avium WGS During Mav-PD Treatment

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Feb 16, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "M. Avium WGS During Mav-PD Treatment," is focused on understanding why some patients with M. avium lung disease continue to test positive for the bacteria in their sputum, even after treatment. The researchers will use a technique called whole genome sequencing to see if these patients are dealing with new strains of the bacteria or if the treatment is not working effectively. By comparing patients from the Toronto/York area with those from other regions, the study aims to gather important information that could help improve treatment outcomes.

To participate in this study, individuals need to be at least 18 years old, have been diagnosed with M. avium lung disease, and have lived continuously in Ontario for the past five years. Participants will be asked to provide sputum samples and consent to study procedures. This study is currently recruiting, and it is a great opportunity for patients who are struggling with persistent or recurrent infections to contribute to important research that may lead to better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 and older
• • Willing to provide informed consent and participate in study procedures
• • Residing continuously in Ontario during the past five years
• • Mav-PD, either initial or recurrent (previously treated patients will be eligible) five years
• • Meet American Thoracic Society (ATS) / Infectious Diseases Society of America (IDSA) NTM disease criteria for Mav-PD
• Exclusion Criteria:
• • Lack of an available pre-treatment M. avium isolate in the PHOL isolate bank
• • The inability to produce sputum either spontaneously or by induction with nebulized hypertonic saline
• • Cavitation \>3 cm internal diameter
• • Known macrolide-resistant MAC infection
• • HIV infection
• • Known diagnosis of cystic fibrosis
• • History of solid organ or hematological transplantation
• • Severe comorbid illness that is reasonably expected to limit survival to \<24 months
• • Residing in mid/north York region (King, Aurora, Newmarket, Whitechurch-Stouffville, East Gwillimbury or Georgina)
• • Having moved between regions (Toronto/southern York region vs non-Toronto/York region vs mid-northern York region) within the past 5 years